---
provider: cyberian
model: deep-research
cached: false
start_time: '2026-01-20T16:54:44.814106'
end_time: '2026-01-20T17:21:50.976782'
duration_seconds: 1626.16
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Pouchitis
  mondo_id: ''
  category: Complex
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    agent_type: claude
    port: 3284
    skip_permissions: true
citation_count: 26
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Pouchitis
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Pouchitis**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

# Pouchitis: Pathophysiology and Molecular Mechanisms

**Disease Identifier:** MONDO:0005312

## Introduction

Pouchitis represents the most common long-term complication following restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) in patients with ulcerative colitis[lusetti-2025-pouchitis-unveiled]. This inflammatory condition affects the surgically constructed ileal reservoir and manifests with characteristic symptoms including increased stool frequency, urgency, abdominal cramping, and rectal bleeding. The clinical significance of pouchitis is substantial, affecting almost one-half of patients within the first 10 years after IPAA surgery[lusetti-2025-pouchitis-unveiled]. The pathophysiology of pouchitis involves a complex interplay of genetic predisposition, microbiome alterations, intestinal barrier dysfunction, and dysregulated immune responses[braga-neto-2025-cellular-mechanisms][shen-2024-pouchitis-pathophysiology]. Understanding these mechanisms at the molecular and cellular levels is essential for developing rational therapeutic strategies and improving patient outcomes.

The disease presents along a clinical spectrum, ranging from acute antibiotic-responsive episodes to chronic antibiotic-refractory inflammation that may require advanced immunosuppressive therapies[shen-2024-pouchitis-pathophysiology]. While approximately 50% of ulcerative colitis patients who undergo IPAA develop pouchitis, only 0-10% of familial adenomatous polyposis (FAP) patients experience this complication[angriman-2014-pouch-microbiota], suggesting that the underlying disease process in ulcerative colitis creates a permissive environment for post-surgical inflammation. This observation has been fundamental in shaping current understanding of pouchitis pathogenesis, pointing toward a model where genetic susceptibility, pre-existing immune dysregulation, and microbiome alterations converge to trigger inflammation in the surgically altered intestinal environment.

Recent investigations have challenged earlier simplistic models that attributed pouchitis solely to bacterial overgrowth or dysbiosis. Contemporary research emphasizes pouchitis as a multifactorial condition involving not only microbial imbalance but also epithelial barrier disruption, innate immune activation, adaptive immune dysregulation, and potentially transmural inflammation extending beyond the mucosal surface[braga-neto-2025-cellular-mechanisms][schieffer-2016-pathogenesis]. This comprehensive review synthesizes current knowledge regarding the molecular pathways, cellular mechanisms, genetic determinants, and phenotypic manifestations of pouchitis, providing a foundation for understanding this complex inflammatory disorder.

## Clinical Context and Epidemiology

The clinical presentation of pouchitis is heterogeneous, reflecting underlying pathophysiological diversity. Pouchitis is classified by duration into acute (symptoms lasting less than 4 weeks) and chronic (symptoms persisting beyond 4 weeks) forms. Further classification based on antibiotic responsiveness distinguishes chronic antibiotic-dependent pouchitis from chronic antibiotic-refractory pouchitis, with important therapeutic and prognostic implications[shen-2024-pouchitis-pathophysiology]. The cumulative incidence of pouchitis increases progressively following IPAA surgery, with rates of approximately 25% at one year, 35% at three years, and 45% at five years post-operatively. A substantial proportion of patients who develop acute pouchitis progress to chronic disease, with retrospective analyses indicating that 29-39% of acute pouchitis cases evolve into chronic pouchitis within a median interval of 0.6-1.1 years after initial diagnosis.

The natural history of pouchitis reveals distinct progression patterns. In a recent population-based study, 84.2% of patients experienced intermittent pouchitis characterized by episodic flares, while 11.6% developed chronic antibiotic-dependent disease requiring continuous or frequently repeated antibiotic therapy, and 4.2% progressed to chronic antibiotic-refractory pouchitis necessitating immunosuppressive or biologic agents. Approximately 10-20% of patients develop Crohn's disease-like pouch inflammation (CDLPI), characterized by stricturing, fistulizing disease, or inflammation resistant to antibiotic therapy, typically manifesting a median of 2.1 years after surgery. This progression to CDLPI raises important diagnostic questions about whether these cases represent de novo Crohn's disease, initially misdiagnosed ulcerative colitis, or a distinct phenotype emerging from the unique environment of the ileal pouch.

The striking difference in pouchitis rates between ulcerative colitis and FAP patients has been central to understanding disease mechanisms. While UC patients demonstrate pouchitis rates approaching 50%, FAP patients rarely develop inflammation despite undergoing identical surgical procedures[angriman-2014-pouch-microbiota][zella-2011-distinct-microbiome]. This observation strongly implicates host immune factors and pre-existing dysbiosis present in UC patients as critical determinants of post-surgical inflammation risk. The surgical creation of an ileal pouch transforms the intestinal environment, exposing ileal mucosa to fecal stasis and high concentrations of bacteria typically found in the colon. In genetically susceptible individuals with pre-existing immune dysregulation, this environmental transformation appears sufficient to trigger sustained inflammatory responses.

## Genetic Susceptibility and Host Factors

Genetic factors play a fundamental role in determining pouchitis susceptibility, with multiple studies identifying specific polymorphisms associated with increased risk of post-IPAA complications. The most robust genetic association involves variants in NOD2 (nucleotide-binding oligomerization domain-containing protein 2), also known as CARD15 (caspase recruitment domain-containing protein 15). In a landmark multicenter study of 714 patients, the NOD2insC polymorphism (rs2066847) emerged as the single nucleotide polymorphism most significantly associated with adverse pouch outcomes, demonstrating odds ratios of 3.2 for chronic pouchitis and 4.3 for Crohn's disease-like phenotypes compared to uncomplicated outcomes[tyler-2013-nod2-polymorphism]. The risk of severe pouchitis increased dramatically with accumulating risk alleles, reaching as high as 92% in patients carrying multiple susceptibility variants[sehgal-2012-genetic-risk-profiling]. These findings establish a clear genetic basis for pouchitis susceptibility and suggest that preoperative genetic profiling may ultimately enable personalized risk stratification and informed surgical decision-making.

The biological significance of NOD2 variants in pouchitis pathogenesis is well established through their known functions in intestinal homeostasis. NOD2 serves as an intracellular pattern recognition receptor that detects bacterial peptidoglycan components, particularly muramyl dipeptide (MDP), derived from both commensal and pathogenic bacteria. Upon ligand binding, NOD2 activates NF-κB and mitogen-activated protein kinase (MAPK) signaling cascades, triggering production of antimicrobial peptides and pro-inflammatory cytokines. Importantly, NOD2 regulates autophagy, a cellular process critical for intracellular bacterial clearance and antigen presentation. Loss-of-function NOD2 variants impair these protective mechanisms, resulting in defective bacterial handling, reduced α-defensin secretion by Paneth cells, and dysregulated inflammatory responses[tyler-2013-nod2-polymorphism]. The convergence of NOD2 genetics in both Crohn's disease and pouchitis suggests shared pathogenic mechanisms involving impaired bacterial sensing and clearance.

Beyond NOD2, additional genetic loci contribute to pouchitis susceptibility. Polymorphisms in TNFSF15 (tumor necrosis factor superfamily member 15, also known as TL1A) have been associated with severe pouchitis risk[sehgal-2012-genetic-risk-profiling]. TNFSF15 encodes a cytokine that promotes T cell activation and inflammatory responses, with genetic variants potentially increasing inflammatory tone in susceptible individuals. Variants in genes encoding components of the NADPH oxidase complex (NOX3, NCF4) and lipid metabolism pathways (DAGLB) have shown associations with Crohn's disease-like complications following IPAA[sehgal-2012-genetic-risk-profiling]. Toll-like receptor polymorphisms, particularly TLR4 variants, have been implicated in pouchitis susceptibility, though the evidence is less robust than for NOD2[braga-neto-2025-cellular-mechanisms]. These genetic associations collectively point toward dysregulated innate immunity, particularly in bacterial sensing and inflammatory signaling pathways, as central to pouchitis pathogenesis.

The genetic architecture of pouchitis susceptibility overlaps substantially with that of inflammatory bowel disease, particularly Crohn's disease. This overlap suggests that patients with UC who carry certain genetic variants may have an underlying immune dysregulation that persists even after removal of the diseased colon, predisposing the ileal pouch to inflammation when exposed to appropriate environmental triggers. The concept of genetic risk profiling for IPAA candidate selection remains investigational but holds promise for identifying high-risk individuals who might benefit from alternative surgical approaches or intensified post-operative monitoring and prophylactic interventions.

## Microbiome Dysbiosis and Bacterial Factors

Microbiome alterations represent a cardinal feature of pouchitis pathogenesis, with multiple lines of evidence demonstrating that the bacterial composition of inflamed pouches differs substantially from that of healthy pouches. Following IPAA surgery, the ileal pouch undergoes a dramatic ecological transformation. The bacterial community shifts from a small intestinal phenotype, characterized by relatively low bacterial density and predominance of facultative anaerobes, to a colonic phenotype dominated by obligate anaerobes[braga-neto-2025-cellular-mechanisms]. This transformation reflects the new functional reality of the pouch as a fecal reservoir, exposing ileal mucosa to bacterial loads and metabolic products characteristic of the colon rather than the terminal ileum.

Comparative microbiome analyses have revealed distinct compositional differences between pouchitis and healthy pouch states. Using 16S rDNA sequencing and length heterogeneity PCR techniques, Zella and colleagues demonstrated statistically significant microbiota differences among UC pouchitis, healthy UC pouches, and healthy FAP pouches[zella-2011-distinct-microbiome]. UC pouchitis samples exhibited elevated levels of Clostridium and Eubacterium genera compared to control groups, while FAP pouches showed higher abundances of Lactobacillus and Streptococcus species. At the phylum level, luminal samples from UC pouchitis patients contained 51.2% Firmicutes compared to 21.2% in FAP pouches, 20.2% Verrucomicrobia versus 3.2% in FAP samples, and markedly reduced Bacteroidetes (17.9% versus 60.5%)[zella-2011-distinct-microbiome]. These compositional shifts suggest that dysbiosis may be central to understanding pouchitis pathogenesis.

Further characterization of pouchitis-associated dysbiosis has identified specific bacterial patterns linked to inflammation. Komanduri and colleagues employed molecular profiling techniques to demonstrate unique microfloral signatures in pouchitis, with persistent colonization by Fusobacter and Enteric species in inflamed tissue and notable absence of Streptococcus species[komanduri-2007-dysbiosis-microflora]. This study provided direct evidence for bacterial involvement in pouchitis pathogenesis by demonstrating dysbiosis in the mucosal biofilm adherent to the epithelium, not merely in luminal contents. The microbial diversity in UC-IPAA patients is reduced compared to FAP-IPAA patients, with increased proportions of Proteobacteria and decreased Bacteroidetes characteristic of UC pouches[angriman-2014-pouch-microbiota]. Importantly, no single pathogenic bacterial species has been consistently identified across pouchitis cases, suggesting that dysbiosis itself—the overall imbalance and altered community structure—rather than specific pathogens, drives inflammatory responses.

The functional consequences of microbiome dysbiosis extend beyond compositional changes to alterations in bacterial metabolism and host-microbe interactions. Patients with pouchitis demonstrate the highest levels of metabolic dysbiosis among IBD phenotypes, with alterations affecting species composition, metabolic pathways, and enzyme profiles that correlate with the degree of intestinal inflammation. Studies examining short-chain fatty acids (SCFAs) and bile acids have yielded mixed results, with some investigations finding no significant differences in fecal SCFA or bile acid concentrations between pouchitis and non-inflamed pouches. However, recent research has identified altered bile acid composition in chronic pouchitis patients, with decreases in Ruminococcaceae and secondary bile acids potentially contributing to pouchitis development, raising the possibility of using secondary bile acids as preventative measures. The broader literature on IBD indicates that SCFA-producing bacteria are typically reduced in inflammatory conditions, and several studies have shown reduced fecal SCFA levels in active IBD. The role of metabolites in pouchitis pathogenesis remains incompletely understood and represents an important area for future investigation.

A critical observation supporting the causal role of microbiota in pouchitis comes from therapeutic responses. The efficacy of antibiotics, particularly metronidazole and ciprofloxacin, in treating acute pouchitis demonstrates that bacterial factors contribute actively to inflammatory pathogenesis. Furthermore, probiotics, especially VSL#3 (a mixture of eight bacterial strains), have shown benefit in preventing pouchitis recurrence and maintaining remission in some patients. Fecal microbiota transplantation has emerged as an experimental therapy, with preliminary studies suggesting potential efficacy in chronic pouchitis, though larger controlled trials are needed. These therapeutic observations establish that modulating the microbiome can alter disease activity, supporting a causal rather than merely correlative relationship between dysbiosis and inflammation.

## Epithelial Barrier Dysfunction and Tight Junction Alterations

The intestinal epithelial barrier serves as the critical interface between the luminal microbial community and the host immune system. Disruption of this barrier is a hallmark of pouchitis pathophysiology, characterized by selective alterations in tight junction protein expression that compromise epithelial integrity and increase paracellular permeability. Studies examining barrier function in pouchitis have consistently demonstrated markedly reduced epithelial resistance compared to non-inflamed pouches and control ileum[landy-2014-innate-immune]. This increased permeability allows luminal antigens, including bacterial products and metabolites, to access the lamina propria and activate immune cells, perpetuating inflammatory responses.

Molecular analysis of tight junction components reveals specific patterns of dysregulation in pouchitis. In patients with chronic pouchitis, epithelial expression of the scaffolding protein zonula occludens-1 (ZO-1) and the barrier-forming protein claudin-1 are significantly reduced compared to healthy pouches[landy-2014-innate-immune][braga-neto-2025-cellular-mechanisms]. Conversely, expression of claudin-2, a pore-forming tight junction protein that increases paracellular permeability, is markedly elevated. Importantly, claudin-2 upregulation appears to be an early event in the development of pouch inflammation, detectable even before overt clinical pouchitis emerges[landy-2014-innate-immune]. This temporal pattern suggests that barrier dysfunction may represent an initiating event rather than solely a consequence of established inflammation. The selective change in tight junction protein composition favors opening of the paracellular pathway, facilitating antigen translocation and contributing to the inflammatory cascade characteristic of pouchitis.

The mechanisms driving tight junction alterations in pouchitis involve both inflammatory mediators and intrinsic epithelial dysfunction. Pro-inflammatory cytokines, particularly TNF-α, IFN-γ, and IL-1β, directly modulate tight junction protein expression and assembly. TNF-α increases claudin-2 expression while reducing claudin-1 and occludin levels through activation of NF-κB signaling pathways. Interferon-γ disrupts tight junction integrity through multiple mechanisms, including redistribution of junctional proteins and cytoskeletal reorganization. The elevated levels of these cytokines in pouchitis tissue[patel-1995-cytokine-production] create a microenvironment that actively promotes barrier disruption. Additionally, bacterial products that translocate across the compromised epithelium can further amplify barrier dysfunction through activation of pattern recognition receptors on epithelial cells, creating a self-perpetuating cycle of barrier compromise and inflammation.

Expression patterns of additional tight junction-associated proteins, including occludin and members of the claudin family (claudin-3, -4, -5, -7), show differential regulation in pouchitis, with the tightening protein claudin-1 being decreased while pore-forming claudin-2 increases. These changes closely resemble the tight junction alterations observed in inflammatory bowel disease, suggesting that pouchitis may represent a recurrence or continuation of IBD-associated epithelial dysfunction in the surgically reconstructed intestine. The similarity between pouchitis and IBD in terms of barrier dysfunction indicates that the inflammatory process in the pouch is characteristic of chronic intestinal inflammation rather than a distinct entity. This observation has important implications for understanding disease pathogenesis and selecting therapeutic targets, as interventions that restore barrier function may provide benefit across the spectrum of chronic inflammatory pouch disorders.

## Innate Immune Activation and Pattern Recognition Receptors

The innate immune system serves as the first line of defense against microbial threats and plays a central role in pouchitis pathogenesis. Disruptions in innate immunity characterize UC pouches and contribute to the development and maintenance of pouch inflammation through multiple mechanisms[landy-2014-innate-immune][braga-neto-2025-cellular-mechanisms]. Pattern recognition receptors (PRRs), particularly Toll-like receptors (TLRs) and NOD-like receptors (NLRs), mediate recognition of bacterial components and initiate inflammatory signaling cascades. In pouchitis, aberrant activation of these receptors drives excessive inflammatory responses to the altered pouch microbiota.

Toll-like receptor expression and signaling are altered in pouchitis. TLR4, which recognizes lipopolysaccharide (LPS) from Gram-negative bacteria, shows increased expression in inflamed pouches[landy-2014-innate-immune][braga-neto-2025-cellular-mechanisms]. This heightened TLR4 expression amplifies responses to the gram-negative bacteria that dominate the pouch microbiome, leading to excessive production of pro-inflammatory mediators. Upon TLR engagement by bacterial ligands, downstream signaling through the adaptor proteins MyD88 and TRIF activates the transcription factor NF-κB, which translocates to the nucleus and drives expression of genes encoding inflammatory cytokines (IL-1β, IL-6, TNF-α), chemokines (IL-8, MIP-2α), and additional immune effectors. Malfunctioning TLR signaling contributes to inflammatory disorders through sustained NF-κB activation, creating a state of chronic immune activation even in the presence of commensal bacteria.

The NF-κB signaling pathway represents a central hub in pouchitis pathogenesis, integrating signals from multiple PRRs and cytokine receptors to coordinate inflammatory gene expression. The canonical NF-κB pathway, triggered by microbial products and pro-inflammatory cytokines such as TNF-α and IL-1β, plays a pivotal role in orchestrating the inflammatory response in pouchitis. NF-κB induces expression of numerous inflammatory mediators and participates in inflammasome regulation. The transcription factor STAT1 (signal transducer and activator of transcription 1) also shows increased activation in mucosal biopsies from inflamed pouches, with STAT1 signaling driving expression of interferon-responsive genes and contributing to the inflammatory milieu. The convergence of NF-κB and STAT pathways amplifies inflammatory responses and promotes immune cell recruitment to the pouch mucosa.

Dendritic cells, which bridge innate and adaptive immunity, demonstrate aberrant phenotypes in pouchitis. These professional antigen-presenting cells show increased expression of activation markers, including CD40, and altered expression of gut-homing markers in patients with pouchitis compared to those with healthy pouches[landy-2014-innate-immune]. Dendritic cells in inflamed pouches display enhanced capacity to activate T cells and drive inflammatory responses. The altered dendritic cell phenotype may contribute to breaking tolerance to commensal bacteria, transforming normally innocuous microbial antigens into targets of pathological immune responses. Macrophages and monocytes in the lamina propria of inflamed pouches release substantial quantities of TNF-α and other pro-inflammatory cytokines, contributing to tissue injury and amplifying inflammation. The persistent activation of these innate immune cells sustains chronic inflammation even when bacterial loads may be controlled by antibiotic therapy, explaining the progression from antibiotic-responsive acute disease to antibiotic-refractory chronic pouchitis.

Neutrophils, the most abundant leukocytes recruited to sites of acute inflammation, play complex roles in pouchitis. Histological examination of inflamed pouches reveals acute inflammatory cell infiltration characterized by neutrophil accumulation and crypt abscesses. Persistent neutrophil activation, exacerbated infiltration, and reduced apoptosis rates contribute to the chronification of intestinal inflammation in IBD and likely play similar roles in pouchitis. Neutrophils release reactive oxygen species, proteases, and additional inflammatory mediators that can damage epithelial cells and perpetuate barrier dysfunction. The communication between neutrophils and dendritic cells further amplifies inflammatory responses, as neutrophil-derived signals promote dendritic cell maturation and activation, creating positive feedback loops that sustain chronic inflammation.

## Adaptive Immunity and Cytokine Networks

While innate immune dysregulation initiates pouchitis, adaptive immunity plays critical roles in sustaining and amplifying inflammation, particularly in chronic disease phenotypes. The inflammatory milieu in pouchitis is characterized by profound alterations in cytokine networks, with marked increases in pro-inflammatory mediators and relative deficiencies in regulatory cytokines. Multiple studies have documented that IL-1β, IL-6, IL-8, and TNF-α secretion levels are significantly elevated in pouchitis and active UC compared to non-inflamed ileoanal pouches and normal controls[patel-1995-cytokine-production]. The pattern of cytokine production in pouchitis closely resembles that observed in ulcerative colitis, with significant correlation (r=0.63, p<0.05) between cytokine levels in the two conditions[patel-1995-cytokine-production]. This similarity supports the hypothesis that pouchitis represents a recurrence or continuation of the inflammatory mechanisms characteristic of UC in the surgically reconstructed intestine.

A critical feature of pouchitis immunopathology is the imbalance between pro-inflammatory and anti-inflammatory cytokines. Studies have demonstrated that histologic lesions of pouchitis associate with mucosal imbalance between IL-8 (a pro-inflammatory chemokine) and IL-10 (an immunoregulatory cytokine)[bulois-2000-il8-il10-imbalance]. Specifically, IL-8 mRNA levels are significantly elevated in patients with severe histologic scores and those displaying crypt abscesses, while the IL-10/IL-8 ratio is significantly reduced[bulois-2000-il8-il10-imbalance]. This imbalance suggests insufficient anti-inflammatory mechanisms to counterbalance pro-inflammatory signals, creating a permissive environment for sustained inflammation. IL-10 deficiency is particularly significant given its critical role in maintaining intestinal immune homeostasis through suppression of pro-inflammatory cytokine production, inhibition of antigen presentation, and promotion of regulatory T cell function.

Comprehensive gene expression profiling has revealed that increased cytokine transcripts in pouchitis reflect the degree of inflammation but not necessarily the underlying disease entity (UC versus CD versus FAP)[schmidt-2006-cytokine-transcripts]. Quantification of 20 different gene transcripts in mucosal biopsies from 87 IPAA patients demonstrated that pro-inflammatory cytokines and chemokines are significantly increased in acute pouchitis independent of the underlying diagnosis[schmidt-2006-cytokine-transcripts]. Strong correlations emerged between disease activity indices and specific markers including myeloid-related protein 14 (MRP-14), IL-8, macrophage inflammatory protein-2α (MIP-2α), and matrix metalloproteinase-1 (MMP-1). These findings suggest that the inflammatory response in pouchitis represents a distinct process from the original IBD, potentially driven primarily by microbial overgrowth and dysbiosis rather than disease-specific autoimmune mechanisms. The uniformity of cytokine patterns across different underlying diagnoses supports viewing pouchitis as a final common pathway of pouch inflammation triggered by environmental factors in the altered intestinal milieu.

T helper cell subsets and their signature cytokines contribute to pouchitis immunopathology. Abnormalities in immunoregulatory cytokines including IL-2, interferon-γ (IFN-γ), IL-4, and IL-10 have been documented in pouchitis[braga-neto-2025-cellular-mechanisms]. The balance between Th1-associated cytokines (IFN-γ, IL-2) and Th2-associated cytokines (IL-4, IL-10) appears disrupted in inflamed pouches, with increased expression of IFN-γ indicative of Th1 polarization. Interferon-γ exerts multiple pro-inflammatory effects including activation of macrophages, enhancement of antigen presentation, and disruption of epithelial tight junctions. The relationship between preoperative T helper cytokine profiles in ileal mucosa and subsequent pouchitis development has been investigated, with some evidence suggesting that pre-existing immune dysregulation predisposes to post-operative complications. The effectiveness of immunosuppressive treatments, including thiopurines and biologic agents targeting TNF-α or integrin-mediated lymphocyte trafficking, in chronic antibiotic-refractory pouchitis supports the conclusion that dysregulated adaptive immunity drives persistent inflammation in severe disease phenotypes.

Beyond classical cytokines, additional inflammatory mediators contribute to pouchitis pathophysiology. Production of cell adhesion molecules, platelet-activating factor, lipoxygenase products, pro-inflammatory neuropeptides, matrix metalloproteinases (MMP-1, MMP-2, MMP-9), and inducible nitric oxide synthase are all increased in inflamed pouches[braga-neto-2025-cellular-mechanisms]. Matrix metalloproteinases, in particular, mediate tissue remodeling and degradation of extracellular matrix components, contributing to mucosal injury and ulceration. The induction of these diverse inflammatory mediators creates a complex inflammatory microenvironment characterized by immune cell activation, epithelial damage, and tissue remodeling. Exposure of peripheral blood and lamina propria lymphocytes to bacterial sonicates from pouchitis induces more intense proliferation compared to sonicates from healthy pouches, suggesting that certain microflora may be pathogenic through activation of local mononuclear cells. This observation directly links the dysbiotic microbiome to adaptive immune activation, providing mechanistic support for the microbiota-immunity axis in pouchitis pathogenesis.

## Paneth Cells and Antimicrobial Peptide Responses

Paneth cells, specialized secretory epithelial cells located at the base of intestinal crypts, play critical roles in intestinal innate immunity through production of antimicrobial peptides, particularly α-defensins. In pouchitis, Paneth cell function and defensin expression patterns show paradoxical alterations that provide insights into disease pathogenesis and progression. A longitudinal study examining defensin expression in pouch biopsies from 32 patients revealed that elevated mucosal levels of α-5 and α-6 defensins correlate with chronic and relapsing pouchitis onset[scarpa-2012-defensin-predictor]. Specifically, high mucosal levels of α-5 defensin (DEFA5) emerged as predictive of chronic/relapsing pouchitis with an area under the curve of 74%, representing a significant biomarker for disease progression[scarpa-2012-defensin-predictor]. At multivariate analysis, mucosal α-5 defensin levels and the number of colony-forming units of mucosa-associated Clostridiaceae species emerged as independent predictors of chronic/relapsing pouchitis, suggesting a link between specific bacterial populations and antimicrobial peptide responses[scarpa-2012-defensin-predictor].

The paradoxical elevation of defensins in pouchitis contrasts sharply with observations in ileal Crohn's disease, where α-defensin production by Paneth cells is characteristically reduced. This distinction suggests fundamentally different pathophysiological mechanisms underlying these two forms of ileal inflammation. In Crohn's disease, NOD2 variants impair Paneth cell function, leading to deficient defensin production and compromised bacterial clearance. In pouchitis, however, elevated defensin expression may represent an exaggerated antimicrobial response to dysbiotic bacterial communities, particularly Clostridiaceae colonization. The correlation between α-5 defensin levels and Clostridiaceae abundance suggests that certain bacterial populations may drive compensatory increases in antimicrobial peptide production, potentially reflecting ongoing host-microbe conflict rather than protective immunity.

The functional significance of elevated defensins in pouchitis remains incompletely understood. One hypothesis posits that increased defensin production represents an appropriate but ultimately insufficient response to pathogenic bacteria, failing to restore microbial homeostasis and instead contributing to sustained inflammation through immune activation. Defensins possess immunomodulatory functions beyond direct antimicrobial activity, including chemokine-like properties that recruit and activate immune cells. Elevated defensin levels could thus amplify inflammation by enhancing recruitment of neutrophils, lymphocytes, and dendritic cells to the pouch mucosa. The utility of α-5 defensin as a predictive biomarker for chronic pouchitis progression warrants prospective validation, as early identification of high-risk patients could enable preemptive therapeutic interventions.

## Cellular Stress Responses: ER Stress and Autophagy

Recent investigations using advanced single-cell profiling techniques have revealed that cellular stress responses, particularly endoplasmic reticulum (ER) stress and autophagy dysregulation, contribute to pouchitis pathogenesis, especially in severe phenotypes. A 2024 single-cell analysis of Crohn's-like disease of the pouch (CDP) identified heightened ER stress across multiple cell types as a distinctive feature of this severe pouchitis variant[cao-2024-singlecell-cdp]. The study found that CDP involves activation of the unfolded protein response (UPR) in immune cells, epithelial cells, and stromal cells, suggesting that ER stress represents a unifying pathogenic mechanism in refractory pouch inflammation[cao-2024-singlecell-cdp]. This discovery positions CDP as a potentially distinct inflammatory bowel disease entity characterized by widespread cellular stress rather than solely immune dysregulation or microbial factors.

The endoplasmic reticulum serves as the principal site for protein folding and quality control within cells. When protein folding capacity becomes overwhelmed by increased demand or reduced function, misfolded proteins accumulate, triggering the UPR. The UPR initiates adaptive responses aimed at restoring ER homeostasis, including upregulation of molecular chaperones, attenuation of protein translation, and enhanced degradation of misfolded proteins through ER-associated degradation (ERAD). However, prolonged or severe ER stress can trigger inflammatory signaling and apoptosis. In inflammatory bowel disease, ER stress has been implicated in epithelial dysfunction and immune activation, with studies demonstrating differential involvement in colonic versus ileal inflammation. The finding that ER stress pervades multiple cellular compartments in CDP suggests that therapeutic strategies targeting the UPR or enhancing protein folding capacity might benefit patients with refractory pouchitis.

Autophagy, a lysosome-dependent degradative pathway essential for clearing damaged organelles, protein aggregates, and intracellular pathogens, intersects with ER stress pathways and NOD2 function in pouchitis pathogenesis. NOD2, the major genetic risk factor for pouchitis, regulates autophagy induction in response to bacterial peptidoglycan detection. Loss-of-function NOD2 variants impair autophagy-mediated bacterial clearance, leading to accumulation of intracellular bacteria and prolonged inflammatory signaling. ER stress also activates autophagy as an adaptive response to clear misfolded proteins and damaged ER membranes. The convergence of NOD2-mediated autophagy defects and ER stress-induced autophagy activation in pouchitis creates complex regulatory dynamics that may determine disease outcomes. Defective autophagy in NOD2 variant carriers could compound ER stress by impairing clearance mechanisms, potentially explaining why genetic susceptibility translates into clinical disease only when environmental triggers (dysbiosis, fecal stasis) create additional cellular stress.

Transcriptomic profiling of ileal pouches has revealed that molecular changes occur remarkably early after IPAA surgery, well before histological inflammation becomes apparent[huang-2017-early-transcriptomic]. In UC patients, the newly created pouch displays a systems-level gain of colon-associated genes and loss of ileum-associated genes even in the absence of inflammation[huang-2017-early-transcriptomic]. This transcriptomic transformation includes enhanced immune response pathways and extracellular matrix remodeling, suggesting that the ileal mucosa undergoes fundamental reprogramming in response to the altered luminal environment. These early molecular changes may represent a vulnerable state predisposing to inflammation when additional insults (dysbiosis, barrier dysfunction, genetic susceptibility) converge. The demonstration that RNA expression changes precede histological abnormalities positions transcriptomic profiling as a potentially sensitive tool for identifying patients at high risk for pouchitis development.

## Transmural Inflammation and Stromal Cell Involvement

Recent conceptual advances have challenged the traditional view of pouchitis as primarily a mucosal inflammatory disorder. Emerging evidence suggests that pouchitis may involve transmural inflammation extending through the full thickness of the pouch wall, similar to patterns observed in Crohn's disease[braga-neto-2025-cellular-mechanisms]. This transmural component has important implications for understanding disease pathogenesis, particularly in chronic antibiotic-refractory pouchitis and Crohn's disease-like pouch inflammation. The recognition that inflammation extends beyond the mucosa helps explain why some patients develop complications such as strictures, fistulas, and abscess formation that are characteristic of transmural inflammatory processes.

A key advancement in understanding pouchitis pathogenesis involves recognizing the active contribution of non-immune cells, particularly stromal cells, to inflammatory perpetuation. Stromal cells, including fibroblasts, myofibroblasts, and mesenchymal stem cells, have traditionally been viewed as passive structural components of intestinal tissue. However, contemporary research demonstrates that stromal cells actively participate in inflammatory responses through production of cytokines, chemokines, growth factors, and extracellular matrix components[braga-neto-2025-cellular-mechanisms]. In chronic inflammation, activated fibroblasts acquire a pro-inflammatory phenotype characterized by increased production of IL-6, IL-8, and stromal cell-derived factor-1 (SDF-1), which recruit and activate immune cells. Stromal cells also secrete matrix metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs), modulating extracellular matrix turnover and tissue remodeling.

The concept of pouchitis as a multicellular disease emphasizes complex interactions among immune cells, epithelial cells, and stromal cells rather than attributing pathogenesis solely to one cell type or compartment[braga-neto-2025-cellular-mechanisms]. This paradigm shift has significant therapeutic implications, suggesting that interventions targeting only bacteria or immune cells may prove insufficient in chronic disease. Stromal cells contribute to establishing inflammatory circuits that persist even when bacterial loads are reduced by antibiotics or immune cells are suppressed by immunosuppressive agents. Fibroblast activation and excessive collagen deposition drive fibrosis and stricture formation in some patients, representing irreversible structural complications that may necessitate surgical revision or pouch excision. Understanding stromal cell biology in pouchitis remains an important frontier for research, with potential to identify novel therapeutic targets for chronic refractory disease.

## Disease Progression and Pathogenic Synthesis

The pathogenesis of pouchitis is best understood through a multifactorial model integrating genetic susceptibility, environmental factors, microbiome alterations, barrier dysfunction, and immune dysregulation. The disease does not result from any single etiological factor but rather emerges from the convergence of multiple pathogenic mechanisms[schieffer-2016-pathogenesis][braga-neto-2025-cellular-mechanisms][shen-2024-pouchitis-pathophysiology]. In genetically susceptible individuals, particularly those carrying NOD2 variants or other IBD-associated risk alleles, the surgical creation of an ileal pouch establishes a permissive environment for inflammation. The pouch functions as a fecal reservoir, exposing ileal mucosa to dramatically altered mechanical forces, bacterial loads, and metabolic products compared to the native terminal ileum.

Following IPAA surgery, the microbiome of the ileal pouch undergoes transformation from a small intestinal to a colonic bacterial community composition. This ecological shift involves fecal stasis, reduced motility, and colonization by anaerobic bacteria that dominate the colonic environment. In patients with underlying ulcerative colitis, pre-existing dysbiosis and immune dysregulation persist even after colectomy, creating a vulnerable host-microbe interface in the pouch. Bacterial components from the dysbiotic microbiome activate pattern recognition receptors (TLRs, NOD2) on epithelial cells and innate immune cells, initiating inflammatory signaling cascades. In patients with defective bacterial sensing due to NOD2 polymorphisms, impaired bacterial clearance and reduced antimicrobial peptide production allow bacterial overgrowth and enhanced antigen exposure.

Epithelial barrier dysfunction emerges as a critical early event, potentially preceding clinically apparent inflammation. Upregulation of claudin-2 and downregulation of ZO-1 and claudin-1 compromise tight junction integrity, increasing paracellular permeability and allowing bacterial antigens to access the lamina propria[landy-2014-innate-immune]. This antigen translocation activates dendritic cells, macrophages, and other innate immune cells, which produce pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8. These cytokines further disrupt barrier function, creating a vicious cycle of barrier compromise and immune activation. Activated dendritic cells migrate to mesenteric lymph nodes where they prime naive T cells, initiating adaptive immune responses. The cytokine milieu in the inflamed pouch favors Th1 polarization with IFN-γ production, while regulatory mechanisms mediated by IL-10 and regulatory T cells prove insufficient to resolve inflammation.

In acute pouchitis, antibiotic therapy can interrupt this inflammatory cascade by reducing bacterial loads and limiting antigen exposure, allowing restoration of immune homeostasis. However, in a substantial proportion of patients, the inflammatory process becomes self-sustaining even when bacterial triggers are controlled. The progression from acute to chronic pouchitis likely involves multiple reinforcing mechanisms. Persistent epithelial barrier dysfunction continues to allow antigen translocation. Adaptive immune responses become established, with infiltrating T cells and B cells producing inflammatory mediators independent of acute bacterial stimulation. Stromal cell activation and tissue remodeling create structural changes that may prevent complete resolution of inflammation. In some cases, transmural inflammation develops with involvement of deeper tissue layers, leading to complications such as strictures and fistulas characteristic of Crohn's disease-like pouch inflammation.

The phenotypic heterogeneity of pouchitis—ranging from intermittent antibiotic-responsive disease to chronic refractory inflammation—likely reflects variable contributions of different pathogenic mechanisms across patients. Those with predominantly microbiota-driven disease respond well to antibiotics and probiotics. Patients with more prominent immune dysregulation require immunosuppressive or biologic therapies. Those developing transmural inflammation and structural complications may ultimately require surgical intervention. The multifactorial nature of pouchitis pathogenesis explains both the clinical heterogeneity and the challenges in developing universally effective therapies. Precision medicine approaches that tailor interventions to the dominant pathogenic mechanisms in individual patients represent a promising future direction.

## Phenotypic Manifestations and Clinical Correlations

The clinical phenotype of pouchitis reflects the underlying pathophysiological processes operating at the molecular and cellular levels. The cardinal symptoms of pouchitis—increased stool frequency, urgency, abdominal cramping, and rectal bleeding—directly correlate with the degree of mucosal inflammation, epithelial barrier disruption, and immune cell infiltration. The Pouchitis Disease Activity Index (PDAI), which incorporates clinical symptoms, endoscopic findings, and histological features, provides a standardized assessment tool that captures the multidimensional nature of pouch inflammation. High cytokine levels and chemokine expression correlate with disease activity scores, establishing quantitative relationships between molecular mediators and clinical severity[schmidt-2006-cytokine-transcripts].

Endoscopic examination reveals characteristic features of pouchitis including mucosal erythema, friability, erosions, ulceration, and exudate formation. These macroscopic findings reflect underlying epithelial injury, vascular changes, and inflammatory cell infiltration. Histologically, active pouchitis demonstrates acute inflammatory cell infiltration with neutrophils forming crypt abscesses, villous atrophy, crypt hyperplasia, and chronic inflammatory infiltrates containing lymphocytes, plasma cells, and eosinophils. The histologic patterns in pouchitis closely resemble those of active ulcerative colitis, supporting mechanistic similarities between the two conditions. The presence of crypt abscesses correlates with elevated IL-8 levels and severe histologic scores[bulois-2000-il8-il10-imbalance], providing direct evidence linking specific inflammatory mediators to tissue pathology.

Extraintestinal manifestations occasionally accompany pouchitis, including arthritis, dermatologic conditions (erythema nodosum, pyoderma gangrenosum), and ocular inflammation (uveitis, episcleritis). These extraintestinal features occur in a subset of patients and likely reflect systemic immune dysregulation and inflammatory mediator effects beyond the intestinal compartment. Primary sclerosing cholangitis, an important extraintestinal manifestation of UC, may persist after colectomy and has been associated with increased pouchitis risk in some studies. The relationship between pouchitis and extraintestinal manifestations remains incompletely characterized but suggests that systemic immune abnormalities contribute to disease pathogenesis in some patients.

The progression from intermittent to chronic pouchitis and the emergence of Crohn's disease-like complications reflect evolution of the underlying pathophysiology. Patients who develop antibiotic-dependent pouchitis likely have persistent dysbiosis and barrier dysfunction that recur promptly when antibiotics are discontinued, but with immune responses that remain partially controlled by bacterial suppression. Those progressing to antibiotic-refractory disease demonstrate immune-mediated inflammation that persists independent of bacterial triggers, potentially involving adaptive immune responses, stromal cell activation, and transmural inflammation. The development of strictures, fistulas, and pre-pouch ileitis indicates transmural inflammatory involvement and tissue remodeling processes similar to those in Crohn's disease, raising questions about whether these cases represent misdiagnosed CD, de novo CD development, or a distinct phenotype emerging from the unique pouch environment.

## Advanced Therapeutics and Targeted Interventions

The therapeutic landscape for pouchitis has evolved substantially with the recognition that chronic antibiotic-refractory disease requires immunomodulation rather than continued antimicrobial therapy. While antibiotics (metronidazole and ciprofloxacin) remain first-line treatment for acute pouchitis, a significant proportion of patients progress to chronic forms requiring alternative approaches. The development of biologic therapies and small molecule immunomodulators has transformed management of refractory pouchitis, with emerging evidence supporting efficacy of agents that target specific inflammatory pathways implicated in disease pathogenesis.

Vedolizumab, a gut-selective monoclonal antibody that blocks α4β7 integrin-mediated lymphocyte trafficking to intestinal tissues, has demonstrated particular promise in chronic pouchitis. By preventing interaction between α4β7 integrin on lymphocytes and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on intestinal endothelium, vedolizumab reduces gut-specific inflammation while preserving systemic immunity. Pooled analysis of clinical studies revealed that 75% of chronic pouchitis patients experienced symptomatic improvement at 12 weeks of vedolizumab therapy, with favorable safety profiles showing adverse events in only up to 15% of patients. The gut-selective mechanism of vedolizumab aligns well with the localized nature of pouchitis, potentially explaining superior tolerability compared to systemic immunosuppressants.

Ustekinumab, a monoclonal antibody targeting the p40 subunit shared by interleukin-12 and interleukin-23, has also shown efficacy in chronic pouchitis. By blocking IL-12/IL-23 signaling, ustekinumab inhibits differentiation and activation of Th1 and Th17 lymphocyte subsets implicated in inflammatory bowel disease pathogenesis. Review of 35 patients with chronic pouchitis treated with ustekinumab revealed clinical response rates of 63%, supporting its use in refractory cases. The absence of reported adverse events in the ustekinumab cohort suggests a favorable risk-benefit profile, though larger controlled trials are needed to definitively establish efficacy and safety.

Janus kinase (JAK) inhibitors represent an emerging class of small molecule therapeutics for chronic antibiotic-refractory pouchitis. These oral agents block intracellular JAK-STAT signaling pathways downstream of multiple cytokine receptors, providing broad immunomodulation. Pooled data on JAK inhibitors (tofacitinib, upadacitinib, filgotinib) in pouchitis demonstrated that 53.3% of patients achieved steroid- and antibiotic-free clinical response at 3 months, with 40% achieving clinical remission. The rapid onset of action characteristic of JAK inhibitors may provide advantages over biologic agents that require longer induction periods, though concerns about systemic immunosuppression and infection risk warrant careful patient selection and monitoring.

Traditional anti-TNF agents (infliximab, adalimumab) retain roles in chronic pouchitis management, particularly in patients with concurrent inflammatory bowel disease activity or established responses to these agents for UC treatment. However, anti-TNF therapy shows higher rates of adverse events compared to vedolizumab or ustekinumab, potentially reflecting less selective immunosuppression. The effectiveness of immunosuppressive treatments supports the conclusion that dysregulated adaptive immunity, rather than purely microbial factors, drives persistent inflammation in chronic antibiotic-refractory pouchitis.

Beyond systemic therapies, local interventions targeting specific pathophysiological mechanisms warrant investigation. Rectal administration of anti-inflammatory agents, barrier-protective compounds, or microbiome-modulating therapies could deliver high local concentrations while minimizing systemic exposure. Fecal microbiota transplantation has shown preliminary promise in small studies, though optimal donor selection, preparation methods, and administration protocols remain to be established. Probiotic therapy, particularly with VSL#3 (a multi-strain formulation), has demonstrated efficacy in preventing pouchitis recurrence and maintaining remission, likely through restoration of beneficial bacterial populations and competitive exclusion of pathogenic species. Mechanistic studies demonstrate that probiotic treatment significantly reduces mucosal expression of pro-inflammatory cytokines including IL-1β, IL-8, and IFN-γ, supporting immune regulatory effects beyond simple microbiome modification.

The identification of ER stress as a pathogenic mechanism in Crohn's-like disease of the pouch suggests potential for novel therapeutic approaches targeting the unfolded protein response. Chemical chaperones that enhance protein folding capacity or selective modulators of UPR signaling pathways could theoretically alleviate cellular stress and reduce inflammation in refractory cases. Similarly, therapies targeting autophagy dysfunction in NOD2 variant carriers might restore bacterial clearance and resolve inflammation, though such precision medicine approaches remain investigational. The heterogeneity of pouchitis phenotypes and underlying pathophysiology emphasizes the need for personalized treatment algorithms that match therapeutic mechanisms to dominant disease drivers in individual patients.

## Open Questions

Despite substantial advances in understanding pouchitis pathophysiology, important questions remain unresolved and represent priorities for future investigation. The fundamental question of why some UC patients develop pouchitis while others remain asymptomatic despite identical surgical procedures and similar microbial exposures has not been definitively answered. While genetic susceptibility factors such as NOD2 polymorphisms contribute to risk stratification, they explain only a portion of disease variance, suggesting that additional genetic, epigenetic, or environmental factors remain to be discovered. Genome-wide association studies (GWAS) specifically focused on pouchitis phenotypes could identify novel susceptibility loci and provide insights into pathogenic mechanisms.

The precise mechanisms driving progression from acute antibiotic-responsive pouchitis to chronic antibiotic-refractory disease require further elucidation. Understanding why inflammatory circuits become self-sustaining in some patients could reveal therapeutic targets for preventing chronicity. The relative contributions of continued microbial dysbiosis versus autonomous immune activation versus stromal cell dysfunction in chronic disease remain incompletely characterized. Longitudinal studies with serial sampling during disease evolution, incorporating multi-omic approaches (metagenomics, metabolomics, transcriptomics, proteomics), could provide insights into the molecular events accompanying phenotypic transitions.

The role of the mycobiome (fungal microbiota) in pouchitis pathogenesis deserves investigation. Recent studies have identified fungal dysbiosis in pouchitis patients, with altered mycobiota composition contributing to inflammation in experimental models. The interactions between bacterial and fungal communities in the pouch ecosystem and their combined effects on host immunity represent an understudied area that could yield novel therapeutic strategies. Similarly, the role of bacteriophages (viruses that infect bacteria) in shaping the pouch microbiome and potentially influencing inflammation has not been systematically examined in pouchitis.

The optimal approach for preoperative risk stratification remains to be established. While genetic profiling shows promise, integrating genetic data with clinical parameters, serological markers (anti-Saccharomyces cerevisiae antibodies, perinuclear anti-neutrophil cytoplasmic antibodies), and preoperative microbiome characteristics could enhance predictive accuracy. Developing and validating comprehensive risk prediction models that enable personalized counseling about IPAA versus alternative surgical options represents an important clinical need. Prospective studies evaluating whether prophylactic interventions (antibiotics, probiotics, anti-inflammatory agents) in high-risk patients can prevent pouchitis development would have significant clinical impact.

The mechanisms underlying response and resistance to specific therapies require deeper investigation. Why do some patients respond to antibiotics while others require immunosuppression? What determines responsiveness to anti-TNF agents versus anti-integrin therapies versus JAK inhibitors? Identifying biomarkers that predict therapeutic responses could enable precision medicine approaches, matching patients to the most appropriate treatments based on their underlying pathophysiology. Mechanistic studies examining how effective therapies modulate the microbiome, epithelial function, and immune responses could reveal pathogenic processes and identify combination strategies that target multiple disease mechanisms simultaneously.

The long-term natural history of pouchitis and factors influencing pouch survival require better characterization. What proportion of patients ultimately require pouch excision? What factors predict pouch failure? Can early aggressive intervention in high-risk patients improve long-term outcomes? Addressing these questions requires large, well-characterized cohorts with extended follow-up and comprehensive data collection regarding disease course, treatments, and outcomes. International registry efforts could provide the statistical power needed to address these questions definitively.

Finally, the relationship between pouchitis and pouch carcinogenesis deserves continued investigation. Dysplasia and cancer can develop in ileal pouches, particularly in patients with long-standing chronic pouchitis and those with concurrent primary sclerosing cholangitis. Understanding the molecular pathways linking chronic inflammation to neoplastic transformation in the pouch could inform surveillance strategies and chemopreventive approaches. Whether the inflammatory mechanisms in pouchitis directly promote carcinogenesis or whether shared underlying factors predispose to both inflammation and neoplasia remains to be determined.

## References

**angriman-2014-pouch-microbiota**
Angriman I, Scarpa M, Castagliuolo I. Relationship between pouch microbiota and pouchitis following restorative proctocolectomy for ulcerative colitis. World J Gastroenterol. 2014;20(29):9665-9674. PMID: 25110406. PMCID: PMC4123357. DOI: 10.3748/wjg.v20.i29.9665.

**braga-neto-2025-cellular-mechanisms**
Braga-Neto MB, et al. Cellular and molecular mechanisms in the pathogenesis of pouchitis: More than just the microbiota. Gut. 2025;74(11):1905-1915. PMID: 40240062. PMCID: PMC12240151. DOI: 10.1136/gutjnl-2024-334445.

**bulois-2000-il8-il10-imbalance**
Bulois P, Tremaine WJ, Maunoury V, et al. Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm Bowel Dis. 2000;6(3):157-164. PMID: 10961587. DOI: 10.1097/00054725-200008000-00001.

**cao-2024-singlecell-cdp**
Cao S, Nguyen KM, Ma K, et al. Mucosal Single-Cell Profiling of Crohn's-Like Disease of the Pouch Reveals Unique Pathogenesis and Therapeutic Targets. Gastroenterology. 2024. PMID: 39084267. DOI: 10.1053/j.gastro.2024.07.025.

**hill-2025-navigating-chronic**
Hill R, Travis S, Ardalan Z. Navigating Chronic Pouchitis: Pathogenesis, Diagnosis, and Management. Gastroenterol Hepatol (N Y). 2025;21(1):46-58. PMID: 39897343. PMCID: PMC11784565.

**huang-2017-early-transcriptomic**
Huang Y, Dalal S, Antonopoulos D, et al. Early transcriptomic changes in the ileal pouch provide insight into the molecular pathogenesis of pouchitis and ulcerative colitis. Inflamm Bowel Dis. 2017;23(3):366-378. PMID: 28221248. PMCID: PMC5988644. DOI: 10.1097/MIB.0000000000001027.

**scarpa-2012-defensin-predictor**
Scarpa M, Grillo A, Scarpa M, et al. Innate immune environment in ileal pouch mucosa: α5 defensin up-regulation as predictor of chronic/relapsing pouchitis. J Gastrointest Surg. 2012;16(1):111-119. PMID: 21983950. DOI: 10.1007/s11605-011-1720-6.

**komanduri-2007-dysbiosis-microflora**
Komanduri S, Gillevet PM, Sikaroodi M, Mutlu E, Keshavarzian A. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol. 2007;5(3):352-360. PMID: 17368235. DOI: 10.1016/j.cgh.2007.01.001.

**landy-2014-innate-immune**
Landy J, Al-Hassi HO, Ronde E, et al. Innate immune factors in the development and maintenance of pouchitis. Inflamm Bowel Dis. 2014;20(11):1942-1949. PMID: 25222658. DOI: 10.1097/MIB.0000000000000182.

**lusetti-2025-pouchitis-unveiled**
Lusetti F, Helfenberger CAM, de Mello MK, Queiroz NSF. Pouchitis unveiled: exploring clinical features, diagnosis, and cutting-edge treatments. Ther Adv Gastroenterol. 2025;18:17562848251316412. PMID: 39877662. PMCID: PMC11773515. DOI: 10.1177/17562848251316412.

**patel-1995-cytokine-production**
Patel RT, Bain I, Youngs D, Keighley MR. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum. 1995;38(8):831-837. PMID: 7634977. DOI: 10.1007/BF02049839.

**schieffer-2016-pathogenesis**
Schieffer KM, Williams ED, Yochum GS, Koltun WA. Review article: the pathogenesis of pouchitis. Aliment Pharmacol Ther. 2016;44(8):817-835. PMID: 27554912. PMCID: PMC5785099. DOI: 10.1111/apt.13780.

**schmidt-2006-cytokine-transcripts**
Schmidt C, Giese T, Ludwig B, et al. Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity. Int J Colorectal Dis. 2006;21(5):419-426. PMID: 16133004. DOI: 10.1007/s00384-005-0024-2.

**sehgal-2012-genetic-risk-profiling**
Sehgal R, Berg A, Polinski JI, et al. Genetic risk profiling and gene signature modeling to predict risk of complications after IPAA. Dis Colon Rectum. 2012;55(3):239-248. PMID: 22469789. DOI: 10.1097/DCR.0b013e31823e2d18.

**shen-2024-pouchitis-pathophysiology**
Shen B. Pouchitis: pathophysiology and management. Nat Rev Gastroenterol Hepatol. 2024;21(7):463-476. PMID: 38664536. DOI: 10.1038/s41575-024-00920-5.

**tyler-2013-nod2-polymorphism**
Tyler AD, et al. The NOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis. Gut. 2013;62(10):1433-1439. PMID: 22879519. DOI: 10.1136/gutjnl-2011-301957.

**zella-2011-distinct-microbiome**
Zella GC, Hait EJ, Glavan T, et al. Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis. Inflamm Bowel Dis. 2011;17(5):1092-1100. PMID: 20845425. DOI: 10.1002/ibd.21460.
